Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year

ZUG, Switzerland - Thursday, 23. July 2026

Ad hoc announcement pursuant to Art. 53 LR

 

(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026.

    Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1.
    Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix.
    Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology.
    Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ramp-up with approvals in 33 International markets, alongside continued investment in science-based innovation and medical education.
    Core EBITDA2 margin expansion of 328 basis points at constant currency, ahead of initial expectations for the first half, with Core EBITDA reaching 802 million USD, up 42.8% year-on-year at constant currency, and a Core EBITDA margin of 25.6%.
    Core EPS3 grew to 2.34 USD, up 68.5% year-on-year, driven by strong Core EBITDA and reduced financing costs.
    Raising 2026 full-year net sales guidance to 19-21% growth at constant currency (previously 17-20%) based on a strong trajectory, and confirming Core EBITDA margin of approximately 26% at constant currency.

 

“Galderma delivered a strong first half of 2026, with broad-based growth across geographies and product categories, reflecting the strength of our integrated dermatology strategy. Our upcoming inclusion in the Swiss Market Index, Switzerland’s leading blue-chip equity index, effective September 21, is an important milestone in our journey as a listed company and further recognition of Galderma’s progress. Building on this momentum, we are raising our full-year net sales growth guidance as we continue to advance our dermatology powerhouse ambition.”
 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA
 
    

 

Commercial performance

Galderma is on a strong trajectory in 2026 to deliver on another year of opportunities, as it continues to execute on its proven, growth-driven integrated dermatology strategy. Growth for the year is expected to be broad-based across its portfolio, complemented by new launches and geographic expansion.

For the first half of 2026, Galderma achieved net sales of 3,134 million USD, surpassing 3 billion USD for the first time in the first six months of a year. Year-on-year net sales growth was 24.6% at constant currency, predominantly driven by volume and complemented by favorable mix. Excluding the anticipated effects of Nemluvio’s gross-to-net pricing evolution, price contributed positively to growth. Growth remained strong in the second quarter of the year, with net sales up 23.8% year-on-year at constant currency.

Net sales growth remained broad-based, with double-digit growth in most of Galderma’s top 10 markets and across all product categories. Galderma continued to outperform the market in each of its product categories.

View full article here - https://www.aetoswire.com/en/news/2307202656441

View source version on businesswire.com: https://www.businesswire.com/news/home/20260722555754/en/

Permalink
https://www.aetoswire.com/en/news/2307202656441

Contacts

For further information:

Media

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Investors

Emil Ivanov
Head of Strategy, Investor Relations and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43